Sponsored by Lilly Diabetes
For the millions of Americans living with diabetes, despite significant advances in treatment, managing blood glucose levels remains a daily struggle, and many people are not meeting their treatment goals.1 In fact, according to research, those on intensive insulin treatment*2 still spend more than 30 percent of the time above target blood glucose levels.3
At Lilly Diabetes, some of the research we conduct includes interviews with groups of people with diabetes to allow us to improve our understanding of the needs and challenges faced by real people every day. Recognizing that so many people struggle to manage blood glucose levels daily, we conducted important research to better understand mealtime insulin experiences and unmet needs of people living with type 1 and type 2 diabetes. In the study, the 30 participants living with diabetes (15 with type 1, 15 with type 2) reported their treatment experience impacted a range of factors like high and low blood glucose levels and psychological and social variables.4
During the study, participants described their treatment experience on insulin, reporting symptoms they associated with high blood glucose such as thirst, exhaustion and irritability as well as symptoms they associated with low blood glucose like sweating, difficulty concentrating and shakiness.4 This demonstrated the wide-ranging impact of mealtime insulin on day-to-day aspects of life, including psychology, mood, social life, work or school and sleep.4
We also learned some important considerations regarding mealtime insulin management. The specific impacts with mealtime insulins that the majority of people noted included psychological and social factors, among other factors.4
With these perspectives in mind, there is an opportunity to advance research and the outcomes we measure. These and other insights help shape how we think about the therapies we develop and the role they may play in the lives of people living with diabetes. At Lilly, we know people work hard to manage their diabetes, which is why we continue to research and develop new medicines, including mealtime insulins.
*Intensive treatment defined in the Diabetes Control and Complications Trial as having a goal of normalization of blood glucose versus conventional treatment,which is defined as having the goal of clinical well-being.
PP-UR-US-0113 02/2021©Lilly USA, LLC 2021. All rights reserved.
1.Foster Nicole, Beck Roy, Miller Kellee, et.al. Stateof Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther.2019; 21(2): 66-72. https://doi.org/10.1089/dia.2018.0384
2.American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Diabetes Care. 2003. 26(supl1): 25-27. https://doi.org/10.2337/diacare.26.2007.S25
3.Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019; 42(3):400‐405. https://doi.org/10.2337/dc18-1444
4.PoonJL,GelhornHL,etal.The Mealtime Insulin Experience: Symptoms and Impacts from the Patient Perspective. Presented at the American Association of Diabetes Educators (AADE) Annual Conference 2019; Aug 9-12.